Neurological and CNS Infections

Bacteria, Virus and Fungi can even affect the Central Nervous System of our body. They may affect brain, spinal cord, neurons at any level. Initial prognosis and diagnosis is essentially required to save the life. Share your research work and help many individuals facing adverse consequences because of these infections

The global Central Nervous System therapeutic market size was worth $77.2 billion in 2016 and is expected to grow at a CAGR of 5.9% during the forecast period. The annual incidence of bacterial CNS infections has been 36.3/100,000 and that of viral infections is 688.0/100 000. 

Sub-Tracks

• Encephalitis
• Prion diseases
• Meningitis
• Brain abscesses

Market Analysis: The market for neurological and central nervous system (CNS) therapeutics, a broader category that includes treatments for a wide range of conditions, is currently valued at approximately $134.42 billion in 2025. It is projected to experience substantial growth, reaching an estimated $185.90 billion by 2030, with a notable compound annual growth rate (CAGR) of 6.70%. This expansion is propelled by several key drivers. Firstly, a globally aging population is leading to a higher prevalence of neurodegenerative diseases, such as Alzheimer's and Parkinson's, which are the fastest-growing segment and are expected to drive significant demand for novel therapies. Secondly, advancements in diagnostics, including neuroimaging and biomarker-based testing, are enabling earlier and more accurate diagnosis, thereby expanding the patient population eligible for treatment. Additionally, a renewed focus on R&D by pharmaceutical companies is leading to the development of cutting-edge treatments like gene therapy, personalized medicine, and AI-driven drug discovery, which are revolutionizing the landscape. North America currently holds the largest market share, fueled by its robust healthcare infrastructure and high R&D investments, while the Asia-Pacific region is poised to be the fastest-growing market due to its large population and improving healthcare expenditure. However, the market faces certain restraints, including high clinical trial failure rates, the substantial cost of advanced therapies, and the persistent challenge of the blood-brain barrier for drug delivery, which can hinder market growth despite the immense clinical need.

For More Details: https://microbiology-infectiousdiseases.peersalleyconferences.com/tracks/neurological-and-cns-infections